Drug-eluting stents vs. bare metal stents in saphenous vein graft disease: Insights from a meta-analysis of 7,090 patients

Circulation Journal

Volumn 75, Issue 2, 2011, Pages 280-289

  Lupi, Alessandro ^a   Navarese, Eliano Pio ^b,d   Lazzero, Maurizio ^a   Sansa, Mara ^a   De Servi, Stefano ^c   Serra, Antonio ^d   Bongo, Angelo Sante ^a   Buffon, Antonio ^b  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Civic Hospital   (Italy)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Angioplasty; Coronary artery bypass grafting; Drug eluting stents; Meta analysis; Stents

Indexed keywords

ARTICLE; BARE METAL STENT; CLINICAL EFFECTIVENESS; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; REVASCULARIZATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VEIN GRAFT DISEASE;

AGED; AGED, 80 AND OVER; ANGIOPLASTY; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; CORONARY ARTERY BYPASS; CORONARY DISEASE; CORONARY RESTENOSIS; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PACLITAXEL; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SAPHENOUS VEIN; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 79251569595     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0186     Document Type: Article

References (63)

1. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996; 28: 616-626.
2. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 2004; 44: 2149-2156.
3. Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post- CABG patients. J Am Coll Cardiol 2002; 40: 1951-1954.
4. Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB 3rd, Werner JA, et al. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med 1997; 337: 740-747.
5. Hanekamp CE, Koolen JJ, Den Heijer P, Schalij MJ, Piek JJ, Bär FW, et al. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: The Venestent study. Catheter Cardiovasc Interv 2003; 60: 452-457.
6. de Jaegere PP, van Domburg RT, Feyter PJ, Ruygrok PN, van der Giessen WJ, van den Brand MJ, et al. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1996; 28: 89-96.
7. Keeley EC, Velez CA, O'Neill WW, Safian RD. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 2001; 38: 659-665.
8. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039.
9. Stettler C, Wandel S, Allemann S, Kastrati A, Morice M, Schömig A, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948.
10. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
11. Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern. Circulation 2007; 115: 1440-1455.
12. John LC. Biomechanics of coronary artery and bypass graft disease: Potential new approaches. Ann Thorac Surg 2009; 87: 331-338.
13. Ribichini F, Pugno F, Ferrero V, Wijns W, Vacca G, Vassanelli C, at al. Long-term histological and immunohistochemical findings in human venous aorto-coronary bypass grafts. Clin Sci (Lond) 2008; 114: 211-220.
14. Bittl JA. Drug-eluting stents for saphenous vein graft lesions: The limits of evidence. J Am Coll Cardiol 2009; 53: 929-930.
15. Brilakis ES, Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Haagen D, et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions: The SOS (Stenting Of Saphenous Vein Grafts) trial. J Am Coll Cardiol 2009; 53: 919-928.
16. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, et al. Randomized double-blind comparison of sirolimus- eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006; 48: 2423-2431.
17. Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Van den Branden F, et al. Increased late mortality after sirolimus- eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized DELAYED RRISC trial. J Am Coll Cardiol 2007; 50: 261-270.
18. Gioia G, Bennassi A, Mohendra R, Chowdhury K, Massood I, Matthai W. Lack of clinical long-term bene?t with the use of a drug eluting stent compared to use of a bare metal stent in saphenous vein grafts. Catheter Cardiovasc Interv 2008; 72: 13-20.
19. Chu WW, Rha SW, Kuchulakanti PK, Cheneau E, Torguson R, Pinnow E, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006; 97: 34-37.
20. Ge L, Iakovou I, Sangiorgi GM, Chieffo A, Melzi G, Cosgrave J, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: Immediate and midterm outcome. J Am Coll Cardiol 2005; 45: 989-994.
21. Brodie BR, Wilson H, Stuckey T, Nussbaum M, Laurent S, Bradshaw B, et al. Outcomes with drug-eluting versus bare-metal stents in saphenous vein graft intervention results from the STENT (strategic transcatheter evaluation of new therapies) group. JACC Cardiovasc Interv 2009; 2: 1105-1112.
22. Lee MS, Shah AP, Aragon J, Jamali A, Dohad S, Kar S, et al. Drugeluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005; 66: 507-511.
23. Wöhrle J, Nusser T, Kestler HA, Kochs M, Hombach V. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus- Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 2007; 96: 70-76.
24. Ellis SG, Kandzari D, Kereiakes DJ, Pichard A, Huber K, Resnic F, et al. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: Results of a multicenter 350-patient case-control study. J Invasive Cardiol 2007; 19: 404-409.
25. Minutello RM, Bhagan S, Sharma A, Slotwiner AJ, Feldman DN, Cuomo LJ, et al. Long-term clinical benefit of sirolimus-eluting stents compared to bare metal stents in the treatment of saphenous vein graft disease. J Interv Cardiol 2007; 20: 458-465.
26. Assali A, Raz Y, Vaknin-Assa H, Ben-Dor I, Brosh D, Teplitsky I, et al. Beneficial 2-years results of drug-eluting stents in saphenous vein graft lesions. EuroIntervention 2008; 4: 108-114.
27. Bansal D, Muppidi R, Singla S, Sukhija R, Zarich S, Mehta JL, et al. Percutaneous intervention on the saphenous vein bypass grafts-- long-term outcomes. Catheter Cardiovasc Interv 2008; 71: 58-61.
28. Jeger RV, Schneiter S, Kaiser C, Bonetti PO, Brunner-La Rocca H, Handke M, et al. Drug-eluting stents compared with bare metal stents improve late outcome after saphenous vein graft but not after large native vessel interventions. Cardiology 2009; 112: 49-55.
29. Kaplan S, Barlis P, Kiris A, Dimopoulos K, Celik S, Di Mario C. Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions. Acute Card Care 2008; 10: 88-92.
30. Latib A, Ferri L, Cosgrave J, Godino C, Bonizzoni E, Romagnoli E, et al. Comparison of long-term (2 year) outcomes of drug-eluting stents and bare-metal stent implantation in saphenous vein graft. Am J Cardiol 2008; 102(8 Suppl): 12-13.
31. Okabe T, Lindsay J, Buch AN, Steinberg DH, Roy P, Slottow TL, et al. Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. Am J Cardiol 2008; 102: 530-534.
32. Ramana RK, Ronan A, Cohoon K, Homan D, Sutherland J, Steen L, et al. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. Catheter Cardiovasc Interv 2008; 71: 886-893.
33. van Twisk PH, Daemen J, Kukreja N, van Domburg RT, Serruys PW. Four-year safety and efficacy of the unrestricted use of sirolimus- and paclitaxel-eluting stents in coronary artery bypass grafts. EuroIntervention 2008; 4: 311-317.
34. Vignali L, Saia F, Manari A, Santarelli A, Rubboli A, Varani E, et al. Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the Registro Regionale AngiopLastiche Emilia-Romagna registry). Am J Cardiol 2008; 101: 947-952.
35. Nair SB, Eichofer J, Clarke B, El-Omar M, Fath-Ordoubadi F, Fraser D, et al. Outcomes of drug-eluting and bare metal stents in saphenous vein graft percutaneous coronary intervention: A single centre experience. Heart 2009; 95: 12.
36. Wilson BH, Humphrey AD, Cedarholm JC, Elliott CM, Haber RH, Kowalchuk GT, et al. Drug-eluting stents are no better than bare metal in vein grafts: Results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group. J Am Coll Cardiol 2007; 49(Suppl 1B): 41B.
37. Goswami NJ, Gaffigan M, Berrio G, Plessa AL, Pfeiffer AM, Markwell SJ, et al. Long-term outcomes of drug-eluting stents versus bare-metal stents in saphenous vein graft disease: Results from the Prairie "Real World" Stent Registry. Catheter Cardiovasc Interv 2010; 75: 93-100.
38. Shishehbor MH, Hawi R, Singh IM, Tuzcu EM, Bhatt DL, Ellis SG, et al. Drug-eluting versus bare-metal stents for treating saphenous vein grafts. Am Heart J 2009; 158(4): 637-643.
39. Douglas S Jr. Are our patients better off with drug-eluting stents in saphenous vein grafts? J Am Coll Cardiol Intv 2009; 2: 1113-1115.
40. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. http://www.cochrane.org/resources/handbook (accessed 10 September, 2009).
41. Stroup DF, Berlin JA, Morton SC, Williamson GD, Rennie D, Moher D, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting: Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
42. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: 3rd Symposium on Systematic Reviews: Beyond the Basics, Oxford, UK, 3-5 July 2000. http://www.ohri.ca/programs/clinical_epidemiology/oxford.html (accessed 10 September, 2009).
43. Fleiss JL. Analysis of data from multiclinics trials. Controlled Clin Trials 1986; 7: 267-275.
44. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
45. Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998; 31: 61-66.
46. Lau J, Ioannidis JPA, Schmid CH. Summing up evidence: One answer is not always enough. Lancet 1998; 351: 123.
47. Foster ED, Fisher LD, Kaiser GC, Myers WO. Comparison of operative mortality for initial and repeat coronary artery bypass grafting: The Coronary Artery Surgical Study (CASS) Registry Experience. Ann Thorac Surg 1984; 38: 563-570.
48. Webb JG, Carere RG, Virmani R, Baim D, Teirstein PS, Whitlow P, et al. Retrieval and analysis of particulate debris following saphenous vein graft intervention. J Am Coll Cardiol 1999; 34: 461-467.
49. Bryan AJ, Angelini GD. The biology of saphenous vein graft occlusion: Etiology and strategies. Curr Opin Cardiol 1994; 9: 641-649.
50. Depre C, Havaux X, Wijns W. Pathology of restenosis in saphenous bypass grafts after long term implantation. Am J Clin Pathol 1998; 110: 378-384.
51. Van Beusekom H, Van Der Giessen W, Van Suylen R, Bosman FT, Serruys PW. Histology after stenting of human saphenous vein bypass grafts: Observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol 1993; 21: 45-54.
52. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Baki TT, et al. "Off-label" stent therapy 2-year comparison of drugeluting versus bare-metal stents. J Am Coll Cardiol 2008; 51: 607-614.
53. Brodie BR, Stuckey T, Downey W, Humphrey A, Bradshaw B, Metzger C, et al. Outcomes and complications with off-label use of drug-eluting stents: Results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group. JACC Cardiovasc Interv 2008; 1: 405-414.
54. Lichtenwalter C, de Lemos JA, Roesle M, Obel O, Holper EM, Haagen D, et al. Clinical presentation and angiographic characteristics of saphenous vein graft failure after stenting: Insights from the SOS (stenting of saphenous vein grafts) trial. JACC Cardiovasc Interv 2009; 2: 855-860.
55. Vermeersch P, Agostoni P. Should degenerated saphenous vein grafts routinely be sealed with drug-eluting stents? J Interv Cardiol 2005; 18: 467-473.
56. Navarese EP, Lupi A, Buffon A, Franchi E, Aurelio A, Sansa M, et al. Meta-analysis of non-randomized studies in interventional cardiology: A critical appraisal. Ital Pub Health (in press).
57. Hara M, Nishino M, Taniike M, Makino N, Kato H, Egami Y, et al. Difference of neointimal formational pattern and incidence of thrombus formation among 3 kinds of stents: An angioscopic study. JACC Cardiovasc Interv 2010; 3: 215-220.
58. Schömig A, Dibra A, Windecker S, Mehilli J, Suárez de Lezo J, Kaiser C, et al. A meta-analysis of 16 randomized trials of sirolimus- eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1373-1380.
59. Kataoka Y, Yasuda S, Morii I, Kawamura A, Miyazaki S. Improved long-term prognosis of elderly women in the era of sirolimus-eluting stents. Circ J 2009; 73: 1219-1227.
60. Lee SR, Jeong MH, Ahn YK, Chae SC, Hur SH, Kim YJ, et al. Clinical safety of drug-eluting stents in the Korea acute myocardial infarction registry: The Korea Acute Myocardial Infarction Registry Investigators. Circ J 2008; 72: 392-398.
61. Kim JS, Kim JS, Kim TH, Fan C, Lee JM, Kim W, et al. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxeleluting stents using optical coherence tomography at 9 months after implantation. Circ J 2010; 74: 320-326.
62. Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, et al. Three-year clinical follow-up of the XIENCE V everolimuseluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009; 2: 1190-1198.
63. Choi CU, Rha SW, Chen KY, Li YJ, Poddar KL, Jin Z, et al. Lack of clinical benefit of improved angiographic results with sirolimuseluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Circ J 2009; 73: 2229-2235.